Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting an 8.2% year-on-year (YOY) increase in revenue to DKK 19.912 billion (USD 2.88 billion). The company is now under the leadership of CEO Charl van Zyl, who took over from Deborah Dunsire in October 2023.
In terms of key brand performance, the depression/schizophrenia therapy Rexulti/Rxulti (brexpiprazole) saw a 20% increase in sales, reaching DKK 4.5 billion (USD 652 million). The depression drug Brintellix/Trintellix (vortioxetine) experienced a 5% growth, amounting to DKK 4.32 billion (USD 625 million). Sales of the schizophrenia drug Abilify Maintena/Asimtufi (aripiprazole) rose by 10% to DKK 3.19 billion, and the migraine preventive treatment Vyepti (eptinezumab) saw a significant leap in sales, increasing by 74% to DKK 1.69 billion.
Regionally, Lundbeck reported robust growth in the US, with sales increasing by 11% to DKK 9.8 billion. The European market also saw an 11% rise in sales, reaching DKK 4.6 billion, while international markets recorded a 2% increase, amounting to DKK 4.99 billion. The US, China, Canada, Spain, and Italy are Lundbeck’s top individual country markets. China and Canada together account for 43% of Lundbeck’s global sales in the category of Other pharmaceuticals.- Flcube.com
